Augmented NRF2 activation protects adult sickle mice from lethal acute chest syndrome. (19th June 2018)

• Record Type: Journal Article
• Authors: Ghosh, Samit; Hazra, Rimi; Ihunnah, Chibueze A.; Weidert, Frances; Flage, Bethany; Ofori‐Acquah, Solomon F.
• Is Part Of: British journal of haematology. Volume 182:Number 2(2018)
• Page Start: 271
• Page End: 275
• Publication Date: 2018-06-19
• Subjects: sickle cell disease -- acute chest syndrome -- haem -- nuclear factor erythroid 2 -- haem oxygenase‐1; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15401
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Acute chest syndrome (ACS) mortality in sickle cell disease (SCD) rises sharply in young adult patients and mechanism‐based prophylaxis is lacking. In SCD, haem oxygenase‐1 (HO‐1) declines with age and ACS is associated with low HO‐1. To test if enhanced HO‐1 can reduce ACS mortality, young SCD mice were treated with D3T (3H‐1, 2‐dithiole‐3‐thione), an activator of nuclear‐factor erythroid 2 like 2, which controls HO‐1 expression, for 3 months. Following haem‐induced ACS, all vehicle‐treated mice succumbed to severe lung injury, while D3T‐treated mice had significantly improved survival. Blocking HO‐1 activity abrogated the D3T effect. Thus HO‐1 may be targeted to reduce ACS severity in adult patients.